Panels of tumor-derived RNA markers in peripheral blood of patients with non-small cell lung cancer: Their dependence on age, gender and clinical stages

Oncotarget

Volumn 7, Issue 31, 2016, Pages 50582-50595

  Chian, Chih Feng ^a   Hwang, Yi Ting ^b   Terng, Harn Jing ^c   Lee, Shih Chun ^a   Chao, Tsui Yi ^d,e   Chang, Hung ^a   Ho, Ching Liang ^a   Wu, Yi Ying ^a   Perng, Wann Cherng ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY   (Taiwan)

^c Advpharma Inc   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Circulating tumor cells; Gene expression profiling; Non small cell lung cancer

Indexed keywords

CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN; DUAL SPECIFICITY PHOSPHATASE 6; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INITIATION FACTOR 2; MINICHROMOSOME MAINTENANCE PROTEIN 4; MOLECULAR MARKER; NEUROFIBROMIN; PROTEIN MDM2; RING FINGER PROTEIN; RNA; STAT2 PROTEIN; TUMOR MARKER;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CPEB4 GENE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; DUSP6 GENE; EARLY CANCER DIAGNOSIS; EIF2S3 GENE; FEMALE; GENDER; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC MARKER; GRB2 GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MCM4 GENE; MDM2 GENE; NF1 GENE; NON SMALL CELL LUNG CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; POLDIP2 GENE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RNF4 GENE; SENSITIVITY AND SPECIFICITY; STAT2 GENE; UPREGULATION; VALIDATION STUDY; WEE1 GENE; A-549 CELL LINE; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION PROFILING; LUNG TUMOR; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; SMOKING; TAIWAN; VERY ELDERLY;

A549 CELLS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; RNA; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; SMOKING; TAIWAN;

EID: 84981357565     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10558     Document Type: Article

References (55)

1. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014; 15:23-34.
2. American Society Cancer: Cancer Facts & Figures 2015. American Cancer Society.
3. She J, Yang P, Hong Q and Bai C. Lung cancer in China: challenges and interventions. Chest. 2013; 143:1117-1126.
4. Putila J, Remick SC and Guo NL. Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One. 2011; 6:e17493.
5. Wang BY, Huang JY, Cheng CY, Lin CH, Ko J and Liaw YP. Lung cancer and prognosis in Taiwan: a populationbased cancer registry. J Thorac Oncol. 2013; 8:1128-1135.
6. William WN, Jr., Lin HY, Lee JJ, Lippman SM, Roth JA and Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009; 136:701-709.
7. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395-409.
8. Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, et al. Results of initial lowdose computed tomographic screening for lung cancer. N Engl J Med. 2013; 368:1980-1991.
9. Okasaka T, Matsuo K, Suzuki T, Ito H, Hosono S, Kawase T, Watanabe M, Yatabe Y, Hida T, Mitsudomi T, Tanaka H, Yokoi K and Tajima K. hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. J Hum Genet. 2009; 54:739-745.
10. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM and Gray JW. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 2002; 62:3636-3640.
11. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, Califano JA, Goodman SN, Westra WH, Hoque MO and Sidransky D. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res. 2011; 17:4494-4503.
12. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007; 356:11-20.
13. Li Y, Dong X, Yin Y, Su Y, Xu Q, Zhang Y, Pang X, Zhang Y and Chen W. BJ-TSA-9, a novel human tumorspecific gene, has potential as a biomarker of lung cancer. Neoplasia. 2005; 7:1073-1080.
14. Krismann M, Todt B, Schroder J, Gareis D, Muller KM, Seeber S and Schutte J. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol. 1995; 13:2769-2775.
15. Du YZ, Gu XH, Li L and Gao F. The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer. J Surg Oncol. 2011; 104:836-840.
16. Peck K, Sher YP, Shih JY, Roffler SR, Wu CW and Yang PC. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 1998; 58:2761-2765.
17. Sher YP, Shih JY, Yang PC, Roffler SR, Chu YW, Wu CW, Yu CL and Peck K. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res. 2005; 11:173-179.
18. Sheu CC, Chang MY, Chang HC, Tsai JR, Lin SR, Chang SJ, Hwang JJ, Huang MS and Chong IW. Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: a highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer. Oncology. 2006; 70:203-211.
19. Henley SJ, Richards TB, Underwood JM, Eheman CR, Plescia M and McAfee TA. Lung cancer incidence trends among men and women-United States, 2005-2009. MMWR Morb Mortal Wkly Rep. 2014; 63:1-5.
20. Showe MK, Vachani A, Kossenkov AV, Yousef M, Nichols C, Nikonova EV, Chang C, Kucharczuk J, Tran B, Wakeam E, Yie TA, Speicher D, Rom WN, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res. 2009; 69:9202-9210.
21. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, Wang C, Ren Z, Zhao Y, Wu S, Zhuang R, Zhang Y, Hu H, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. 2012; 130:1620-1628.
22. Cheng M, Chen Y, Yu X, Tian Z and Wei H. Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer. 2008; 8:156.
23. Zander T, Hofmann A, Staratschek-Jox A, Classen S, Debey-Pascher S, Maisel D, Ansen S, Hahn M, Beyer M, Thomas RK, Gathof B, Mauch C, Delank KS, et al. Bloodbased gene expression signatures in non-small cell lung cancer. Clin Cancer Res. 2011; 17:3360-3367.
24. Kossenkov AV, Dawany N, Evans TL, Kucharczuk JC, Albelda SM, Showe LC, Showe MK and Vachani A. Peripheral immune cell gene expression predicts survival of patients with non-small cell lung cancer. PLoS One. 2012; 7:e34392.
25. Mitas M, Hoover L, Silvestri G, Reed C, Green M, Turrisi AT, Sherman C, Mikhitarian K, Cole DJ, Block MI and Gillanders WE. Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003; 5:237-242.
26. Owens DM and Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 2007; 26:3203-3213.
27. Messina S, Frati L, Leonetti C, Zuchegna C, Di Zazzo E, Calogero A and Porcellini A. Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene. 2011; 30:3813-3820.
28. Giubellino A, Burke TR, Jr. and Bottaro DP. Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets. 2008; 12:1021-1033.
29. Momand J, Jung D, Wilczynski S and Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998; 26:3453-3459.
30. Gottfried ON, Viskochil DH and Couldwell WT. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus. 2010; 28:E8.
31. Ortiz-Zapater E, Pineda D, Martinez-Bosch N, Fernandez-Miranda G, Iglesias M, Alameda F, Moreno M, Eliscovich C, Eyras E, Real FX, Mendez R and Navarro P. Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med. 2012; 18:83-90.
32. Xu H and Liu B. CPEB4 is a candidate biomarker for defining metastatic cancers and directing personalized therapies. Med Hypotheses. 2013; 81:875-877.
33. Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y, Birrer MJ, Nishimura M and Dosaka-Akita H. Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer. Lung Cancer. 2011; 72:229-237.
34. Gan N, Du Y, Zhang W and Zhou J. Increase of Mcm3 and Mcm4 expression in cervical squamous cell carcinomas. Eur J Gynaecol Oncol. 2010; 31:291-294.
35. Ishimi Y, Okayasu I, Kato C, Kwon HJ, Kimura H, Yamada K and Song SY. Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. Eur J Biochem. 2003; 270:1089-1101.
36. Saydam O, Senol O, Schaaij-Visser TB, Pham TV, Piersma SR, Stemmer-Rachamimov AO, Wurdinger T, Peerdeman SM and Jimenez CR. Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. J Proteome Res. 2010; 9:485-494.
37. Clifford JL, Walch E, Yang X, Xu X, Alberts DS, Clayman GL, El-Naggar AK, Lotan R and Lippman SM. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res. 2002; 8:2067-2072.
38. Kumar A, Kumar Dorairaj S, Prabhakaran VC, Prakash DR and Chakraborty S. Identification of genes associated with tumorigenesis of meibomian cell carcinoma by microarray analysis. Genomics. 2007; 90:559-566.
39. Mitra R, Lee J, Jo J, Milani M, McClintick JN, Edenberg HJ, Kesler KA, Rieger KM, Badve S, Cummings OW, Mohiuddin A, Thomas DG, Luo X, et al. Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. Clin Cancer Res. 2011; 17:2934-2946.
40. Gamero AM, Young MR, Mentor-Marcel R, Bobe G, Scarzello AJ, Wise J and Colburn NH. STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila). 2010; 3:495-504.
41. Yoshida T, Tanaka S, Mogi A, Shitara Y and Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol. 2004; 15:252-256.
42. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
43. Lee H, Kim JM, Huang SM, Park SK, Kim DH, Kim do H, Lee CS, Suh KS, Yi ES and Kim KH. Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma. Pathol Res Pract. 2011; 207:428-432.
44. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K and Levine AJ. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormonedependent manner. Cancer Res. 2006; 66:5104-5110.
45. Adami HO, Persson I, Hoover R, Schairer C and Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 1989; 44:833-839.
46. Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Florenes VA and Holm R. High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer. 2013; 13:288.
47. Lou F, Sima CS, Rusch VW, Jones DR and Huang J. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. Ann Thorac Surg. 2014; 98:1755-1760; discussion 1760-1751.
48. Uramoto H and Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014; 3:242-249.
49. Chang YT, Huang CS, Yao CT, Su SL, Terng HJ, Chou HL, Chou YC, Chen KH, Shih YW, Lu CY, Lai CH, Jian CE, Lin CH, et al. Gene expression profile of peripheral blood in colorectal cancer. World J Gastroenterol. 2014; 20:14463-14471.
50. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G and Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques. 2004; 37:112-114, 116, 118-119.
51. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.
52. Croce MV, Colussi AG, Price MR and Segal-Eiras A. Identification and characterization of different subpopulations in a human lung adenocarcinoma cell line (A549). Pathol Oncol Res. 1999; 5:197-204.
53. Hosmer DW and Lemeshow S. 2000. Applied Logistic Regression. New York: John Wiley & Sons, Inc.
54. Schulz, KF and Grimes, DA. 2006. The LANCET. Handbook of Essential Concepts in Clinical Research. Elsevier.
55. Dawson B and Trapp G. 2004. Basic & Clinical Biostatistics, 4th Edition, International Edition, McGraw Hill.